Overview
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
Status:
Completed
Completed
Trial end date:
2015-07-01
2015-07-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This registry will evaluate long-term safety and efficacy of deferasirox in children with transfusional iron overload.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novartis PharmaceuticalsTreatments:
Deferasirox
Criteria
Inclusion Criteria:- History of transfusion-dependent anemia.
- History of iron overload
Exclusion Criteria:
- Patients with non-transfusional hemosiderosis.
Other protocol-defined inclusion/exclusion criteria may apply.